SE9801288D0 - Vaccine delivery system and metod of production - Google Patents

Vaccine delivery system and metod of production

Info

Publication number
SE9801288D0
SE9801288D0 SE9801288A SE9801288A SE9801288D0 SE 9801288 D0 SE9801288 D0 SE 9801288D0 SE 9801288 A SE9801288 A SE 9801288A SE 9801288 A SE9801288 A SE 9801288A SE 9801288 D0 SE9801288 D0 SE 9801288D0
Authority
SE
Sweden
Prior art keywords
delivery system
vaccine
vaccine delivery
polymer particle
production
Prior art date
Application number
SE9801288A
Other languages
English (en)
Swedish (sv)
Inventor
Hans Carlsson
Anette Larsson
Erik Soederlind
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9801288A priority Critical patent/SE9801288D0/xx
Publication of SE9801288D0 publication Critical patent/SE9801288D0/xx
Priority to AU40662/99A priority patent/AU765118B2/en
Priority to JP2000543160A priority patent/JP4759134B2/ja
Priority to PCT/SE1999/000582 priority patent/WO1999052550A1/en
Priority to US09/308,435 priority patent/US6838089B1/en
Priority to EP99924075A priority patent/EP1071457B1/en
Priority to AT99924075T priority patent/ATE545432T1/de
Priority to JP2011001576A priority patent/JP2011140491A/ja

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/105Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/04Solvent extraction of solutions which are liquid
    • B01D11/0403Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
SE9801288A 1998-04-14 1998-04-14 Vaccine delivery system and metod of production SE9801288D0 (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE9801288A SE9801288D0 (sv) 1998-04-14 1998-04-14 Vaccine delivery system and metod of production
AU40662/99A AU765118B2 (en) 1998-04-14 1999-04-09 Polymer particle vaccine delivery system
JP2000543160A JP4759134B2 (ja) 1998-04-14 1999-04-09 ポリマー粒子ワクチンデリバリーシステム
PCT/SE1999/000582 WO1999052550A1 (en) 1998-04-14 1999-04-09 Polymer particle vaccine delivery system
US09/308,435 US6838089B1 (en) 1998-04-14 1999-04-09 Antigen delivery system and method of production
EP99924075A EP1071457B1 (en) 1998-04-14 1999-04-09 Polymer particle vaccine delivery system
AT99924075T ATE545432T1 (de) 1998-04-14 1999-04-09 Abgabevorrichtung für impfstoff auf basis von polymerpartikeln
JP2011001576A JP2011140491A (ja) 1998-04-14 2011-01-07 ポリマー粒子ワクチンデリバリーシステム

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801288A SE9801288D0 (sv) 1998-04-14 1998-04-14 Vaccine delivery system and metod of production

Publications (1)

Publication Number Publication Date
SE9801288D0 true SE9801288D0 (sv) 1998-04-14

Family

ID=20410947

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9801288A SE9801288D0 (sv) 1998-04-14 1998-04-14 Vaccine delivery system and metod of production

Country Status (7)

Country Link
US (1) US6838089B1 (https=)
EP (1) EP1071457B1 (https=)
JP (2) JP4759134B2 (https=)
AT (1) ATE545432T1 (https=)
AU (1) AU765118B2 (https=)
SE (1) SE9801288D0 (https=)
WO (1) WO1999052550A1 (https=)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
AU7247000A (en) * 2000-01-11 2001-07-19 Givaudan Sa Composite materials
GB0010371D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
EP2241309A3 (en) * 2001-07-10 2012-12-26 Corixa Corporation Methods for encapsulation of proteins and adjuants in microspheres
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
MXPA05011343A (es) 2003-05-08 2005-12-12 Nektar Therapeutics Uk Ltd Materiales particulados.
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
SI21639A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
KR100753116B1 (ko) * 2004-12-22 2007-08-29 경북대학교 산학협력단 세포 배양용 나노섬유 지지체
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
WO2007011707A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
GB0602637D0 (en) * 2006-02-09 2006-03-22 Glaxo Group Ltd Novel process
EP1834651A1 (en) * 2006-03-15 2007-09-19 Universiteit Gent Compositions and methods for veterinary vaccination
US20100119827A1 (en) * 2006-04-25 2010-05-13 Research Foundation Of The City University Of New York Polymer submicron particle preparation by surfactant-mediated precipitation
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
WO2008042909A2 (en) 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
CN101678388B (zh) * 2006-10-23 2013-12-11 米歇尔技术公司 用于在涂覆过程中为基底充电的保持器
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
BRPI0810370A2 (pt) * 2007-04-17 2014-10-29 Micell Technologies Inc Stent revestido, e, método para preparar um stent
WO2008148013A1 (en) * 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
US20100172845A1 (en) * 2007-05-29 2010-07-08 Board Of Regents Of The University Of Texas System Compositions and methods for treating mycobacterial infections
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
SG192523A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
ES2524699T3 (es) * 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US9060931B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060926B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8725420B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060934B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8603495B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8798932B2 (en) * 2008-10-31 2014-08-05 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8545857B2 (en) * 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US20100111857A1 (en) * 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US20100111834A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US9050070B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111831A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for surface abrasion with frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8551505B2 (en) * 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050251B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8721583B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8603494B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111841A1 (en) * 2008-10-31 2010-05-06 Searete Llc Compositions and methods for surface abrasion with frozen particles
US20100111836A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US8485861B2 (en) * 2008-10-31 2013-07-16 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8788212B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8545855B2 (en) * 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111835A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US9072799B2 (en) * 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8793075B2 (en) * 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050317B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CA2756307C (en) * 2009-03-23 2017-08-08 Micell Technologies, Inc. Peripheral stents having layers and reinforcement fibers
CA2756386C (en) * 2009-03-23 2019-01-15 Micell Technologies, Inc. Drug delivery medical device
US20100256746A1 (en) * 2009-03-23 2010-10-07 Micell Technologies, Inc. Biodegradable polymers
JP5464573B2 (ja) * 2009-03-31 2014-04-09 独立行政法人産業技術総合研究所 中空粒子の製造方法
WO2010120552A2 (en) * 2009-04-01 2010-10-21 Micell Technologies, Inc. Coated stents
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
US9803060B2 (en) * 2009-09-10 2017-10-31 Bridgestone Corporation Compositions and method for making hollow nanoparticles from metal soaps
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
JP2011207988A (ja) * 2010-03-29 2011-10-20 Sumitomo Chemical Co Ltd 樹脂用の加工安定化剤、該加工安定化剤を含む樹脂組成物、および樹脂の加工安定性を向上させる方法
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US20140356396A1 (en) * 2011-08-25 2014-12-04 Brian L. Pulliam Rotavirus preparations with excess calcium ions and high viscosities that ensure viability at elevated temperatures
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US8852648B2 (en) * 2012-11-06 2014-10-07 Rochal Industries, Llp Delivery of biologically-active agents using volatile, hydrophobic solvents
AU2014248508B2 (en) 2013-03-12 2018-11-08 Micell Technologies, Inc. Bioabsorbable biomedical implants
CN105188741A (zh) 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
HUE052599T2 (hu) 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
AU2015311704B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
ES2821761T3 (es) * 2015-07-09 2021-04-27 Evonik Operations Gmbh Proceso de preparación de micropartículas de copolímero de poli(glicolida-co-lactida)
CA3007036A1 (en) 2015-12-14 2017-06-22 Technische Universitat Munchen Helicobacter pylori vaccines
EP3272354A1 (en) 2016-07-20 2018-01-24 Technische Universität München Agents and methods for the prevention or treatment of h. pylori infections
WO2018039465A1 (en) * 2016-08-25 2018-03-01 Selecta Biosciences, Inc. Polyester polymer matrices for the delivery of allergens
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
KR102170146B1 (ko) * 2019-03-05 2020-10-26 서울대학교산학협력단 Pca 공정을 이용한 배양액의 결정화 장치 및 방법
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038139A (en) * 1976-07-16 1977-07-26 G. D. Searle & Co., Limited Cell culture medium
US4919929A (en) 1984-02-01 1990-04-24 Stolle Research & Development Corporation Mammal immunization
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8919819D0 (en) 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
US5622649A (en) 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
AU2316892A (en) 1991-06-27 1993-01-25 Emory University Multiple emulsions and methods of preparation
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
ATE143803T1 (de) 1992-12-22 1996-10-15 Univ Cincinnati Orale verabreichung von immunologischen aktiven biomolekülen und anderen therapeutischen proteinen
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
WO1995011010A1 (en) * 1993-10-22 1995-04-27 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines
DE69415684T2 (de) 1993-10-22 1999-06-10 Genentech Inc., San Francisco, Calif. Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
AR003125A1 (es) * 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
GB9514285D0 (en) * 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
WO1999003448A1 (en) * 1997-07-14 1999-01-28 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
EP1227724B1 (de) * 1999-10-26 2004-04-14 Bayer CropScience GmbH Herbizide mittel
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials

Also Published As

Publication number Publication date
JP2011140491A (ja) 2011-07-21
US6838089B1 (en) 2005-01-04
WO1999052550A1 (en) 1999-10-21
JP4759134B2 (ja) 2011-08-31
AU4066299A (en) 1999-11-01
JP2002516822A (ja) 2002-06-11
AU765118B2 (en) 2003-09-11
EP1071457A1 (en) 2001-01-31
EP1071457B1 (en) 2012-02-15
ATE545432T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
SE9801288D0 (sv) Vaccine delivery system and metod of production
GB2199328B (en) Use of a 5' untranslated leader sequence of an rna virus to enhance translation
Lepage et al. Purification and characterization of the sea urchin embryo hatching enzyme
TR200103149T2 (tr) Virüs ve mikoplazmanın korunması için yöntemler
ATE296839T1 (de) Antikörper zur krebsbehandlung und -diagnose
NZ504936A (en) Simultaneous administration of polynucleotide and delayed release polypeptide encoded by the polynucleotide to enhance an immune response of nucleic acid vaccination
DK0957935T3 (da) Chlamydia-vacciner og immunogene præparater indeholdende et ydre membran-antigen samt fremgangsmåde til fremstilling deraf
DK699488D0 (da) Magnetiserbare komposit-partikler til biologisk anvendelse og fremgangsmaade til fremstilling af saadanne partikler
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
NO20011656L (no) Medikamentavleveringssystemer med mukosaopprinnelse og dyreanvendelser
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
GB9817805D0 (en) Use of a composition
DE69614390D1 (de) Antiwachstumwirksame proteine aus oozyten von rana pipiens
EP0804219A4 (en) Composition containing inhibin and its use
DE69623652D1 (de) Formulierung zur peptidfreisetzung
DE60036555D1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
JPS57144983A (en) Preparation of physiologically active substance
WO2001054707A3 (de) Veränderung von oberflächenproteomem durch aminopeptidase-inhibitoren
AU673344B2 (en) Vaccines based on streptokinase
ES8304801A1 (es) Un metodo para preparar una vacuna contra vibrio anguillarum
SE0101030D0 (sv) Immunogenic cell surface proteins of helicobacter pylori
WO1991000348A3 (de) Modifizierte vp1/p2a regionen des rhinoviralen systems
EP1372691A4 (en) MUCINPEPTIDE WITH IMMUNOSIBLE PROPERTIES
KARAGYAN Ag-banded Karyotypes in Six Species of Jewel-Beetles
DE59611353D1 (de) Transketolase-verwandtes protein